A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

14673

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease
High Cardiovascular Risk
Obesity
Overweight
Type 2 Diabetes

Interventions

DRUG: Lorcaserin hydrochloride
DRUG: Placebo

Sponsor

Eisai Inc.

Collaborators

[object Object]